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background: Immune monitoring (IM) as measured by adenosine triphosphate release from activated lymphocytes has been used to guide 
management of immunosuppressive therapy after cardiac transplantation. However, it is not known whether IM assay scores are associated with 
coronary plaque progression by intravascular ultrasound (IVUS).
Methods: Between March 2010 and September 2011, early IM assays at 2 months post cardiac transplantation (ImmuKnow; Cylex, Columbia, 
MD), as well as baseline and 1-year IVUS were performed on 47 heart transplant recipients. Patients were divided into quartiles by their IM assay 
score. Maximal intimal area, average percent stenosis and plaque volume were measured in a blinded fashion. One way ANOVA was performed, and 
additionally, plaque progression was contrasted between those in the highest quartile against those in the remaining three quartiles.
results: Mean age at transplantation was 55.3 ± 12.9 years and 27.7% of recipients were female. IM assays were measured at 63.3 ± 17.1 days 
after transplantation. Mean IM assays for quartiles 1 to 4 were 60.7 (range: 5 - 103), 175.6 (range: 106 - 245), 293.5 (range: 246 - 390) and 
588.0 (range: 422 - 855) ng ATP/ml, respectively. In one way ANOVA analysis, p-values were significant for changes in maximal intimal area (p = 
0.003), average percent stenosis (p < 0.001) and plaque volume (p < 0.001). Planned contrast revealed that patients with an elevated IM assay in 
the highest quartile had a significantly increased progression of maximal intimal area (4.3 ± 3.7 versus 1.4 ± 1.2 mm^2/year, p = 0.029), average 
percent stenosis (14.3 ± 10.0 versus 4.7 ± 3.9 %/year, p = 0.010) and plaque volume (2.2 ± 1.8 versus 0.6 ± 0.5 mm^3/mm/year, p = 0.016), as 
compared with those in the remaining three quartiles.
conclusions: Elevated IM assay at 2 months post cardiac transplantation is associated with increased progression of maximal intimal area, 
average percent stenosis, and plaque volume by IVUS in the first year after transplantation. These findings suggest the potential of IM in the tailoring 
of immunosuppressive regimens to minimize development or progression of cardiac allograft vasculopathy.
